Global Biosimilar Monoclonal Antibodies Revenue Is Nearly 1500 M USD In 2017
Warning: date() expects parameter 2 to be long, string given in /www/wwwroot/www.globalinforesearch.com/static/themes/default/info_detail.php on line 32
In the last several years, global market of Biosimilar Monoclonal Antibodies developed rapidly, with an average growth rate of 32.6%. In 2017, global revenue of Biosimilar Monoclonal Antibodies is nearly 1500 M USD; the actual production is about 4.05 M Units.
Patent expirations on essential biological drugs is expected to create wider scope for potential opportunities for key players in the biosimilar monoclonal antibodies market in the near future.
However, lack of appropriate standards, stringent government regulations in developed countries, and high research and development costs for development of biosimilar monoclonal antibodies are some major factors restraining growth of the global biosimilar monoclonal antibodies market.
The classification of Biosimilar Monoclonal Antibodies includes Infliximab, Rituximab, Trastuzumab, Adalimumab and Other, and the sales proportion of Infliximab in 2017 is about 36.5%, and the proportion is increasing trend from 2013 to 2018.
Biosimilar Monoclonal Antibodies is widely used for Oncology, Autoimmune?Disease and Others. The most proportion of Biosimilar Monoclonal Antibodies is sales in Autoimmune?Disease, and the consumption proportion is about 85.6% in 2017.
Europe is the largest consumption place, with a revenue market share nearly 51.4% in 2017. Following Europe, North America is the second largest consumption place with the revenue market share of 26.2%, China is also an important sales region for the Biosimilar Monoclonal Antibodies.
Market competition is intense. Celltrion, Pfizer (Hospira), 3SBIO, Novartis (Sandoz), etc. are the leaders of the industry. They hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.